Canaccord analyst William Plovanic raised the firm’s price target on Staar Surgical to $79 from $76 and keeps a Buy rating on the shares. The analyst met with management for a fireside chat and he believes investors are focused mostly on China and the US launch including barriers to adoption such as facilities and overcoming the mindset that EVO is a niche product. He believes the company has a gameplan and possibly regulatory tailwinds to continue to garner market share in the United States and worldwide.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Weekly Market Update: Stocks Gain Ahead of Earnings Season
- Staar Surgical reports preliminary Q4 revenue $64M, consensus $65.01M
- This Insider Just Bought Staar Surgical (NASDAQ:STAA) Shares Worth $9.1M
- Staar Surgical price target lowered to $67 from $80 at BTIG
- Staar Surgical price target lowered to $85 from $91 at Stephens